Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review

Dr. André Mattar

Monoclonal antibody-based therapies have substantially improved outcomes in breast cancer, particularly through HER2-directed treatment strategies, but have also introduced important cardiovascular toxicities that require careful recognition and management. This narrative review summarizes current evidence on cardiotoxicity associated with monoclonal antibody therapies used in breast cancer, with emphasis on HER2- targeted antibodies, antibody-drug conjugates, and selected […]